Regen Biopharma, Inc. income statement RGBP

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended Jun 30, 2026, Regen Biopharma, Inc. reported revenue of $59,065, about flat from the same quarter a year earlier. It recorded a net loss of $637,785. Operating income came to $24,528, an operating margin of 41.5%. Diluted earnings per share were $0.00.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q3 FY2026 Jun 30, 2026	Q2 FY2026 Mar 31, 2026	Q1 FY2026 Dec 31, 2025	Q2 FY2025 Mar 31, 2025	Q1 FY2025 Dec 31, 2024	Q4 FY2024 Sep 30, 2024	Q3 FY2024 Jun 30, 2024	Q2 FY2024 Mar 31, 2024
Revenue	0 -0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +86.7%	0 +86.7%	0 +217.2%	0 +0.0%	0 +0.0%
Research and development	0	0 -100.0%	0 -94.5%	0 +341.8%	—	—	—	0 -27.8%	0 +10.1%
Selling, general and administrative	0 +279.1%	0 -54.9%	0 +140.5%	0 +1641.6%	0 +42.2%	0 +7.2%	0 +148.0%	0 +78.1%	0 -49.7%
Operating income	-1 -167.2%	0 +160.2%	-0 -35.6%	-1 -798.7%	-0 -12.1%	-0 +50.0%	-0 -44.5%	-0 -26.8%	-0 -28.2%
Pretax income	-1	-1 -281.2%	1 +5225.2%	-1 -87.8%	-0	-1	—	—	—
Income tax	—	0	0	0	—	—	—	—	—
Net income	—	-1	1 +5225.2%	-1 -87.8%	-0 +84.2%	-1 -255.6%	-0 +16.7%	-0 -31.1%	-0 -122.7%
Basic EPS	—	0.00 +100.0%	0.00	-0.01 +92.3%	0.00 +100.0%	-0.13 -225.0%	-0.01 +79.0%	-0.03 -2.2%	-0.03 +10.2%
Diluted EPS	—	0.00 +100.0%	0.00	-0.01 +92.3%	0.00	-0.13 -225.0%	-0.01	-0.03	—
Weighted average shares, basic	231 +1312.3%	616 +2491.5%	185 +758.0%	100 +2323.4%	22 +424.4%	4 +14.3%	5 +12.0%	4 +24.6%	4 +148.1%
Weighted average shares, diluted	231 +1312.3%	616 +2491.5%	185 +758.0%	100 +2323.4%	22	4 +14.3%	5	4	—
Other measures
Interest coverage	-4.72x	0.81x	-5.61x	-20.77x	-5.08x	-2.42x	-4.26x	-6.15x	—
Margins
Operating margin	-339.81%	41.53%	-260.24%	-933.93%	-191.91%	-103.92%	-143.86%	-182.79%	-319.44%
Pretax margin	-501.43%	-1,079.80%	1,679.38%	-1,638.62%	-32.77%	-872.57%	—	—	—
Profit margin	—	-1,079.80%	1,679.38%	-1,638.62%	-32.77%	-872.57%	-456.07%	-220.30%	-387.02%
Effective tax rate	—	—	0.00%	—	—	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RGBP (OTC), RGBPP (OTC)
Fiscal year ends: September 30
Incorporated in: NV
Headquarters: La Mesa, CA
SEC filer status: , Emerging growth company
SEC CIK: 1589150

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.